<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 42 - THE PUBLIC HEALTH AND WELFARE</title></head><body>
<span style="font-weight:bold;font-size:12pt;">42 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 2003 Edition</span><br/>
<span style="font-size:10pt">Title 42 - THE PUBLIC HEALTH AND WELFARE</span><br/>
<span style="font-size:10pt">CHAPTER 6A - PUBLIC HEALTH SERVICE</span><br/>
<span style="font-size:10pt">SUBCHAPTER XXI - RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME</span><br/>
<span style="font-size:10pt">Part A - Administration of Research Programs</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- documentid:42_-ch6A-scXXI-Part_A currentthrough:20040119 documentPDFPage:988 -->
<!-- itempath:/420/CHAPTER 6A/SUBCHAPTER XXI/Part A -->
<!-- itemsortkey:420ABVD -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6A-PUBLIC HEALTH SERVICE!@!SUBCHAPTER XXI-RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME!@!Part A-Administration of Research Programs -->
<!-- field-start:structuralhead -->
<h3 class="part-head"><cap-smallcap>Part A&mdash;Administration of Research Programs</cap-smallcap></h3>
<!-- field-end:structuralhead -->
<!-- field-start:footnote -->
<p class="footnote"><a href="#300bb-8_1" name="300bb-8_1_target"><sup>1</sup>&nbsp;So in original. Probably should be preceded by &ldquo;section&rdquo;.</a></p>
<!-- field-end:footnote -->

<!-- documentid:42_300cc  usckey:42000000003000000000000cc00000000 currentthrough:20040119 documentPDFPage:988 -->
<!-- itempath:/420/CHAPTER 6A/SUBCHAPTER XXI/Part A/Sec. 300cc -->
<!-- itemsortkey:420ABVE -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6A-PUBLIC HEALTH SERVICE!@!SUBCHAPTER XXI-RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME!@!Part A-Administration of Research Programs!@!Sec. 300cc -->
<!-- field-start:head -->
<h3 class="section-head">&sect;300cc. Requirement of annual comprehensive report on all expenditures by Secretary with respect to acquired immune deficiency syndrome</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) In general</h4>
<p class="statutory-body">Not later than December 1 of each fiscal year, the Secretary shall prepare and submit to the Congress a report on the expenditures by the Secretary of amounts appropriated for the preceding fiscal year with respect to acquired immune deficiency syndrome.</p>
<h4 class="subsection-head">(b) Inclusion of certain information</h4>
<p class="statutory-body">The report required in subsection (a) of this section shall, with respect to acquired immune deficiency syndrome, include&mdash;</p>
<!-- PDFPage:989 --><p class="statutory-body-1em">(1) for each program, project, or activity with respect to such syndrome, a specification of the amount obligated by each office and agency of the Department of Health and Human Services;</p>
<p class="statutory-body-1em">(2) a summary description of each such program, project, or activity;</p>
<p class="statutory-body-1em">(3) a list of such programs, projects, or activities that are directed towards members of minority groups;</p>
<p class="statutory-body-1em">(4) a description of the extent to which programs, projects, and activities described in paragraph (3) have been coordinated between the Director of the Office of Minority Health and the Director of the Centers for Disease Control and Prevention;</p>
<p class="statutory-body-1em">(5) a summary of the progress made by each such program, project, or activity with respect to the prevention and control of acquired immune deficiency syndrome;</p>
<p class="statutory-body-1em">(6) a summary of the evaluations conducted under this subchapter; and</p>
<p class="statutory-body-1em">(7) any report required in this chapter to be submitted to the Secretary for inclusion in the report required in subsection (a) of this section.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(July 1, 1944, ch. 373, title XXIII, &sect;2301, as added Pub. L. 100&ndash;607, title II, &sect;201(4), Nov. 4, 1988, 102 Stat. 3063; amended Pub. L. 102&ndash;531, title III, &sect;312(d)(16), Oct. 27, 1992, 106 Stat. 3505.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:priorprovisions-note -->
<h4 class="note-head">Prior Provisions</h4>
<p class="note-body">A prior section 300cc, act July 1, 1944, &sect;2301, was successively renumbered by subsequent acts and transferred, see section 238 of this title.</p>
<!-- field-end:priorprovisions-note -->
<!-- field-start:amendment-note -->
<h4 class="note-head">Amendments</h4>
<p class="note-body">1992&mdash;Subsec. (b)(4). Pub. L. 102&ndash;531 substituted &ldquo;Centers for Disease Control and Prevention&rdquo; for &ldquo;Centers for Disease Control&rdquo;.</p>
<!-- field-end:amendment-note -->
<!-- field-start:terminationdate-note -->
<h4 class="note-head">Termination of Reporting Requirements</h4>
<p class="note-body">For termination, effective May 15, 2000, of provisions of law requiring submittal to Congress of any annual, semiannual, or other regular periodic report listed in House Document No. 103&ndash;7 (in which a report required under this section is listed on page 94), see section 3003 of Pub. L. 104&ndash;66, as amended, and section 1(a)(4) [div. A, &sect;1402(1)] of Pub. L. 106&ndash;554, set out as notes under section 1113 of Title 31, Money and Finance.</p>
<!-- field-end:terminationdate-note -->
<!-- field-start:miscellaneous-note -->
<h4 class="note-head">Development of Rapid HIV Test</h4>
<p class="note-body">Pub. L. 106&ndash;345, title V, &sect;502, Oct. 20, 2000, 114 Stat. 1353, provided that:</p>
<p class="note-body">&ldquo;(a) <cap-smallcap>Expansion, Intensification, and Coordination of Research and Other Activities.&mdash;</cap-smallcap></p>
<p class="note-body-1em">&ldquo;(1) <cap-smallcap>In general</cap-smallcap>.&mdash;The Director of NIH shall expand, intensify, and coordinate research and other activities of the National Institutes of Health with respect to the development of reliable and affordable tests for HIV disease that can rapidly be administered and whose results can rapidly be obtained (in this section referred to as &lsquo;rapid HIV test&rsquo;).</p>
<p class="note-body-1em">&ldquo;(2) <cap-smallcap>Report to congress</cap-smallcap>.&mdash;The Director of NIH shall periodically submit to the appropriate committees of Congress a report describing the research and other activities conducted or supported under paragraph (1).</p>
<p class="note-body-1em">&ldquo;(3) <cap-smallcap>Authorization of appropriations</cap-smallcap>.&mdash;For the purpose of carrying out this subsection, there are authorized to be appropriated such sums as may be necessary for each of the fiscal years 2001 through 2005.</p>
<p class="note-body">&ldquo;(b) <cap-smallcap>Premarket Review of Rapid HIV Tests.&mdash;</cap-smallcap></p>
<p class="note-body-1em">&ldquo;(1) <cap-smallcap>In general</cap-smallcap>.&mdash;Not later than 90 days after the date of the enactment of this Act [Oct. 20, 2000], the Secretary, in consultation with the Director of the Centers for Disease Control and Prevention and the Commissioner of Food and Drugs, shall submit to the appropriate committees of the Congress a report describing the progress made towards, and barriers to, the premarket review and commercial distribution of rapid HIV tests. The report shall&mdash;</p>
<p class="note-body-2em">&ldquo;(A) assess the public health need for and public health benefits of rapid HIV tests, including the minimization of false positive results through the availability of multiple rapid HIV tests;</p>
<p class="note-body-2em">&ldquo;(B) make recommendations regarding the need for the expedited review of rapid HIV test applications submitted to the Center for Biologics Evaluation and Research and, if such recommendations are favorable, specify criteria and procedures for such expedited review; and</p>
<p class="note-body-2em">&ldquo;(C) specify whether the barriers to the premarket review of rapid HIV tests include the unnecessary application of requirements&mdash;</p>
<p class="note-body-3em">&ldquo;(i) necessary to ensure the efficacy of devices for donor screening to rapid HIV tests intended for use in other screening situations; or</p>
<p class="note-body-3em">&ldquo;(ii) for identifying antibodies to HIV subtypes of rare incidence in the United States to rapid HIV tests intended for use in screening situations other than donor screening.</p>
<p class="note-body">&ldquo;(c) <cap-smallcap>Guidelines of Centers for Disease Control and Prevention</cap-smallcap>.&mdash;Promptly after commercial distribution of a rapid HIV test begins, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall establish or update guidelines that include recommendations for States, hospitals, and other appropriate entities regarding the ready availability of such tests for administration to pregnant women who are in labor or in the late stage of pregnancy and whose HIV status is not known to the attending obstetrician.&rdquo;</p>
<h4 class="note-head">Limitation on Expenditures for AIDS and HIV Activities</h4>
<p class="note-body">Pub. L. 104&ndash;146, &sect;11, May 20, 1996, 110 Stat. 1373, provided that: &ldquo;Notwithstanding any other provision of law, the total amounts of Federal funds expended in any fiscal year for AIDS and HIV activities may not exceed the total amounts expended in such fiscal year for activities related to cancer.&rdquo;</p>
<h4 class="note-head">Vaccines for Human Immunodeficiency Virus</h4>
<p class="note-body">Pub. L. 103&ndash;43, title XIX, &sect;1901(b), June 10, 1993, 107 Stat. 200, provided that:</p>
<p class="note-body">&ldquo;(1) <cap-smallcap>In general</cap-smallcap>.&mdash;The Secretary of Health and Human Services, acting through the National Institutes of Health, shall develop a plan for the appropriate inclusion of HIV-infected women, including pregnant women, HIV-infected infants, and HIV-infected children in studies conducted by or through the National Institutes of Health concerning the safety and efficacy of HIV vaccines for the treatment and prevention of HIV infection. Such plan shall ensure the full participation of other Federal agencies currently conducting HIV vaccine studies and require that such studies conform fully to the requirements of part 46 of title 45, Code of Federal Regulations.</p>
<p class="note-body">&ldquo;(2) <cap-smallcap>Report</cap-smallcap>.&mdash;Not later than 180 days after the date of the enactment of this Act [June 10, 1993], the Secretary of Health and Human Services shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives, and the Committee on Labor and Human Resources of the Senate, a report concerning the plan developed under paragraph (1).</p>
<p class="note-body">&ldquo;(3) <cap-smallcap>Implementation</cap-smallcap>.&mdash;Not later than 12 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall implement the plan developed under paragraph (1), including measures for the full participation of other Federal agencies currently conducting HIV vaccine studies.</p>
<p class="note-body">&ldquo;(4) <cap-smallcap>Authorization of appropriations</cap-smallcap>.&mdash;For the purpose of carrying out this subsection, there are author<!-- PDFPage:990 -->ized to be appropriated such sums as may be necessary for each of the fiscal years 1994 through 1996.&rdquo;</p>
<h4 class="note-head">Requirement of Certain Research Studies</h4>
<p class="note-body">Section 203 of Pub. L. 100&ndash;607 provided that after consultation with Director of National Center for Health Services Research and Health Care Technology Assessment, the Secretary of Health and Human Services, acting through the Director of Centers for Disease Control, was to conduct a study for purpose of determining mortality rates with respect to acquired immune deficiency syndrome among individuals of various groups at risk of such syndrome, among various geographic areas, and among individuals with varying financial resources for payment of health care services, with a report to be submitted to Congress not later than 18 months after Nov. 4, 1988, and further directed Secretary to request the National Academy of Sciences and other similar appropriate nonprofit institutions to report to the Secretary findings made by such institutions with respect to the manner in which research on, and the development of, vaccines and drugs for the prevention and treatment of acquired immune deficiency syndrome and related conditions can be enhanced by the establishment of consortia designed to combine and share resources needed for such research and development, consisting of businesses involved in such research and development, of nonprofit research institutions, or of combinations of such businesses and such institutions, and the appropriate participation, if any, of the Federal Government in such consortia, with a report to be submitted to Congress not later than 1 year after Nov. 4, 1988.</p>
<h4 class="note-head">National Commission on Acquired Immune Deficiency Syndrome</h4>
<p class="note-body">Subtitle D (&sect;&sect;241&ndash;249) of title II of Pub. L. 100&ndash;607, as amended by Pub. L. 100&ndash;690, title II, &sect;2602(a), Nov. 18, 1988, 102 Stat. 4233, established National Commission on Acquired Immune Deficiency Syndrome for the purpose of promoting the development of a national consensus on policy concerning acquired immune deficiency syndrome and of studying and making recommendations for a consistent national policy concerning such syndrome, including financing of health care needs and research, dissemination of information to prevent spread of such syndrome, behavioral changes needed to combat such syndrome, and related civil rights issues, provided for membership of Commission, reports, executive director and staff of Commission, powers, and appropriations, and provided for termination of Commission 30 days after submission of its final report.</p>
<!-- field-end:miscellaneous-note -->
<!-- field-start:executivedocument-note -->
<h4 class="note-head">Ex. Ord. No. 12963. Presidential Advisory Council on HIV/AIDS</h4>
<p class="note-body">Ex. Ord. No. 12963, June 14, 1995, 60 F.R. 31905, as amended by Ex. Ord. No. 13009, June 14, 1996, 61 F.R. 39799 [30799], provided:</p>
<p class="note-body">By the authority vested in me as President by the Constitution and the laws of the United States of America, I hereby direct the Secretary of Health and Human Services to exercise her discretion as follows:</p>
<p class="note-body"><cap-smallcap>Section</cap-smallcap> 1. <em>Establishment</em>. (a) The Secretary of Health and Human Services (the &ldquo;Secretary&rdquo;) shall establish an HIV/AIDS Advisory Council (the &ldquo;Advisory Council&rdquo; or the &ldquo;Council&rdquo;), to be known as the Presidential Advisory Council on HIV/AIDS. The Advisory Council shall be composed of not more than 35 members to be appointed or designated by the Secretary. The Advisory Council shall comply with the Federal Advisory Committee Act, as amended (5 U.S.C. App.).</p>
<p class="note-body">(b) The Secretary shall designate a Chairperson from among the members of the Advisory Council.</p>
<p class="note-body"><cap-smallcap>Sec</cap-smallcap>. 2. <em>Functions</em>. The Advisory Council shall provide advice, information, and recommendations to the Secretary regarding programs and policies intended to (a) promote effective prevention of HIV disease, (b) advance research on HIV and AIDS, and (c) promote quality services to persons living with HIV disease and AIDS. The functions of the Advisory Council shall be solely advisory in nature. The Secretary shall provide the President with copies of all written reports provided to the Secretary by the Advisory Council.</p>
<p class="note-body"><cap-smallcap>Sec</cap-smallcap>. 3. <em>Administration</em>. (a) The heads of executive departments and agencies shall, to the extent permitted by law, provide the Advisory Council with such information as it may require for purposes of carrying out its functions.</p>
<p class="note-body">(b) Any members of the Advisory Council that receive compensation shall be compensated in accordance with Federal law. Committee members may be allowed travel expenses, including per diem in lieu of subsistence, to the extent permitted by law for persons serving intermittently in the Government service (5 U.S.C. section 5701&ndash;5707).</p>
<p class="note-body">(c) To the extent permitted by law, and subject to the availability of appropriations, the Department of Health and Human Services shall provide the Advisory Council with such funds and support as may be necessary for the performance of its functions.</p>
<p class="note-body"><cap-smallcap>Sec</cap-smallcap>. 4. <em>General Provisions</em>. (a) Notwithstanding the provisions of any other Executive order, any functions of the President under the Federal Advisory Committee Act that are applicable to the Advisory Council, except that of reporting annually to the Congress, shall be performed by the Department of Health and Human Services, in accordance with the guidelines and procedures established by the Administrator of General Services.</p>
<p class="note-body">(b) This order is intended only to improve the internal management of the executive branch, and it is not intended to create any right, benefit, or trust responsibility, substantive or procedural, enforceable at law or equity by a party against the United States, its agencies, it officers, or any person.</p>
<p class="presidential-signature">William J. Clinton.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- field-end:executivedocument-note -->
<!-- field-end:notes -->
<!-- field-start:secref -->
<h4 class="note-head">Section Referred to in Other Sections</h4>
<!-- field-end:secref -->
<!-- field-start:sectionreferredto -->
<p class="note-body">This section is referred to in sections 300cc&ndash;1, 300cc&ndash;41, 300ee&ndash;22 of this title.</p>
<!-- field-end:sectionreferredto -->

<!-- documentid:42_300cc-1  usckey:42000000003000000000000cc00010000 currentthrough:20040119 documentPDFPage:990 -->
<!-- itempath:/420/CHAPTER 6A/SUBCHAPTER XXI/Part A/Sec. 300cc-1 -->
<!-- itemsortkey:420ABVF -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6A-PUBLIC HEALTH SERVICE!@!SUBCHAPTER XXI-RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME!@!Part A-Administration of Research Programs!@!Sec. 300cc-1 -->
<!-- field-start:head -->
<h3 class="section-head">&sect;300cc&ndash;1. Requirement of expediting awards of grants and contracts for research</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) In general</h4>
<p class="statutory-body">The Secretary shall expedite the award of grants, contracts, and cooperative agreements for research projects relating to acquired immune deficiency syndrome (including such research projects initiated independently of any solicitation by the Secretary for proposals for such research projects).</p>
<h4 class="subsection-head">(b) Time limitations with respect to certain applications</h4>
<p class="statutory-body">(1) With respect to programs of grants, contracts, and cooperative agreements described in subsection (a) of this section, any application submitted in response to a solicitation by the Secretary for proposals pursuant to such a program&mdash;</p>
<p class="statutory-body-1em">(A) may not be approved if the application is submitted after the expiration of the 3-month period beginning on the date on which the solicitation is issued; and</p>
<p class="statutory-body-1em">(B) shall be awarded, or otherwise finally acted upon, not later than the expiration of the 6-month period beginning on the expiration of the period described in subparagraph (A).</p>
<br class="Q04" />
<p class="statutory-body">(2) If the Secretary makes a determination that it is not practicable to administer a program referred to in paragraph (1) in accordance with the time limitations described in such <!-- PDFPage:991 -->paragraph, the Secretary may adjust the time limitations accordingly.</p>
<h4 class="subsection-head">(c) Requirements with respect to adjustments in time limitations</h4>
<p class="statutory-body">With respect to any program for which a determination described in subsection (b)(2) of this section is made, the Secretary shall&mdash;</p>
<p class="statutory-body-1em">(1) if the determination is made before the Secretary issues a solicitation for proposals pursuant to the program, ensure that the solicitation describes the time limitations as adjusted by the determination; and</p>
<p class="statutory-body-1em">(2) if the determination is made after the Secretary issues such a solicitation for proposals, issue a statement describing the time limitations as adjusted by the determination and individually notify, with respect to the determination, each applicant whose application is submitted before the expiration of the 3-month period beginning on the date on which the solicitation was issued.</p>
<h4 class="subsection-head">(d) Annual reports to Congress</h4>
<p class="statutory-body">Except as provided in subsection (e) of this section, the Secretary shall annually prepare, for inclusion in the comprehensive report required in section 300cc of this title, a report&mdash;</p>
<p class="statutory-body-1em">(A) summarizing programs for which the Secretary has made a determination described in subsection (b)(2) of this section, including a description of the time limitations as adjusted by the determination and including a summary of the solicitation issued by the Secretary for proposals pursuant to the program; and</p>
<p class="statutory-body-1em">(B) summarizing applications that&mdash;</p>
<p class="statutory-body-2em">(i) were submitted pursuant to a program of grants, contracts, or cooperative agreements referred to in paragraph (1) of subsection (b) of this section for which a determination described in paragraph (2) of such subsection has not been made; and</p>
<p class="statutory-body-2em">(ii) were not processed in accordance with the time limitations described in such paragraph (1).</p>
<h4 class="subsection-head">(e) Quarterly reports for fiscal year 1989</h4>
<p class="statutory-body">For fiscal year 1989, the report required in subsection (d) of this section shall, not less than quarterly, be prepared and submitted to the Committee on Energy and Commerce of the House of Representatives and the Committee on Labor and Human Resources of the Senate.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(July 1, 1944, ch. 373, title XXIII, &sect;2302, as added Pub. L. 100&ndash;607, title II, &sect;201(4), Nov. 4, 1988, 102 Stat. 3063.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:priorprovisions-note -->
<h4 class="note-head">Prior Provisions</h4>
<p class="note-body">A prior section 300cc&ndash;1, act July 1, 1944, &sect;2302, was successively renumbered by subsequent acts and transferred, see section 238a of this title.</p>
<!-- field-end:priorprovisions-note -->
<!-- field-start:changeofname-note -->
<h4 class="note-head">Change of Name</h4>
<p class="note-body">Committee on Energy and Commerce of House of Representatives treated as referring to Committee on Commerce of House of Representatives by section 1(a) of Pub. L. 104&ndash;14, set out as a note preceding section 21 of Title 2, The Congress. Committee on Commerce of House of Representatives changed to Committee on Energy and Commerce of House of Representatives, and jurisdiction over matters relating to securities and exchanges and insurance generally transferred to Committee on Financial Services of House of Representatives by House Resolution No. 5, One Hundred Seventh Congress, Jan. 3, 2001.</p>
<!-- field-end:changeofname-note -->
<!-- field-end:notes -->

<!-- documentid:42_300cc-2  usckey:42000000003000000000000cc00020000 currentthrough:20040119 documentPDFPage:991 -->
<!-- itempath:/420/CHAPTER 6A/SUBCHAPTER XXI/Part A/Sec. 300cc-2 -->
<!-- itemsortkey:420ABVG -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6A-PUBLIC HEALTH SERVICE!@!SUBCHAPTER XXI-RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME!@!Part A-Administration of Research Programs!@!Sec. 300cc-2 -->
<!-- field-start:head -->
<h3 class="section-head">&sect;300cc&ndash;2. Requirements with respect to processing of requests for personnel and administrative support</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) In general</h4>
<p class="statutory-body">The Director of the Office of Personnel Management or the Administrator of General Services, as the case may be, shall respond to any priority request made by the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, or the Director of the National Institutes of Health, not later than 21 days after the date on which such request is made. If the Director of the Office of Personnel Management or the Administrator of General Services, as the case may be, does not disapprove a priority request during the 21-day period, the request shall be deemed to be approved.</p>
<h4 class="subsection-head">(b) Notice to Secretary and to Assistant Secretary for Health</h4>
<p class="statutory-body">The Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, and the Director of the National Institutes of Health, shall, respectively, transmit to the Secretary and the Assistant Secretary for Health a copy of each priority request made under this section by the agency head involved. The copy shall be transmitted on the date on which the priority request involved is made.</p>
<h4 class="subsection-head">(c) &ldquo;Priority request&rdquo; defined</h4>
<p class="statutory-body">For purposes of this section, the term &ldquo;priority request&rdquo; means any request that&mdash;</p>
<p class="statutory-body-1em">(1) is designated as a priority request by the Administrator of the Substance Abuse and Mental Health Services Administration, the Director of the Centers for Disease Control and Prevention, the Commissioner of Food and Drugs, or the Director of the National Institutes of Health; and</p>
<p class="statutory-body-1em">(2)(A) is made to the Director of the Office of Personnel Management for the allocation of personnel to carry out activities with respect to acquired immune deficiency syndrome; or</p>
<p class="statutory-body-1em">(B) is made to the Administrator of General Services for administrative support or space in carrying out such activities.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(July 1, 1944, ch. 373, title XXIII, &sect;2303, as added Pub. L. 100&ndash;607, title II, &sect;201(4), Nov. 4, 1988, 102 Stat. 3064; amended Pub. L. 102&ndash;321, title I, &sect;&sect;161, 163(b)(7), July 10, 1992, 106 Stat. 375, 376; Pub. L. 102&ndash;531, title III, &sect;312(d)(17), Oct. 27, 1992, 106 Stat. 3505.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:priorprovisions-note -->
<h4 class="note-head">Prior Provisions</h4>
<p class="note-body">A prior section 300cc&ndash;2, act July 1, 1944, &sect;2303, was successively renumbered by subsequent acts and transferred, see section 238b of this title.</p>
<!-- field-end:priorprovisions-note -->
<!-- field-start:amendment-note -->
<h4 class="note-head">Amendments</h4>
<p class="note-body">1992&mdash;Subsec. (a). Pub. L. 102&ndash;531 substituted &ldquo;Centers for Disease Control and Prevention&rdquo; for &ldquo;Centers for Disease Control&rdquo;.</p>
<p class="note-body">Pub. L. 102&ndash;321, &sect;161, substituted &ldquo;Administrator of the Substance Abuse and Mental Health Services Ad<!-- PDFPage:992 -->ministration&rdquo; for &ldquo;Administrator of the Alcohol, Drug Abuse, and Mental Health Administration&rdquo;.</p>
<p class="note-body">Subsec. (b). Pub. L. 102&ndash;531 substituted &ldquo;Centers for Disease Control and Prevention&rdquo; for &ldquo;Centers for Disease Control&rdquo;.</p>
<p class="note-body">Pub. L. 102&ndash;321, &sect;163(b)(7)(A), substituted &ldquo;Administrator of the Substance Abuse and Mental Health Services Administration&rdquo; for &ldquo;Administrator of the Alcohol, Drug Abuse, and Mental Health Administration&rdquo;.</p>
<p class="note-body">Subsec. (c)(1). Pub. L. 102&ndash;531 substituted &ldquo;Centers for Disease Control and Prevention&rdquo; for &ldquo;Centers for Disease Control&rdquo;.</p>
<p class="note-body">Pub. L. 102&ndash;321, &sect;163(b)(7)(B), substituted &ldquo;Administrator of the Substance Abuse and Mental Health Services Administration&rdquo; for &ldquo;Administrator of the Alcohol, Drug Abuse, and Mental Health Administration&rdquo;.</p>
<!-- field-end:amendment-note -->
<!-- field-start:effectivedate-amendment-note -->
<h4 class="note-head">Effective Date of 1992 Amendment</h4>
<p class="note-body">Amendment by Pub. L. 102&ndash;321 effective Oct. 1, 1992, see section 801(c) of Pub. L. 102&ndash;321, set out as a note under section 236 of this title.</p>
<!-- field-end:effectivedate-amendment-note -->
<!-- field-end:notes -->

<!-- documentid:42_300cc-3  usckey:42000000003000000000000cc00030000 currentthrough:20040119 documentPDFPage:992 -->
<!-- itempath:/420/CHAPTER 6A/SUBCHAPTER XXI/Part A/Sec. 300cc-3 -->
<!-- itemsortkey:420ABVH -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6A-PUBLIC HEALTH SERVICE!@!SUBCHAPTER XXI-RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY SYNDROME!@!Part A-Administration of Research Programs!@!Sec. 300cc-3 -->
<!-- field-start:head -->
<h3 class="section-head">&sect;300cc&ndash;3. Establishment of Research Advisory Committee</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) In general</h4>
<p class="statutory-body">After consultation with the Commissioner of Food and Drugs, the Secretary, acting through the Director of the National Institute of Allergy and Infectious Diseases, shall establish within such Institute an advisory committee to be known as the AIDS Research Advisory Committee (hereafter in this section referred to as the &ldquo;Committee&rdquo;).</p>
<h4 class="subsection-head">(b) Composition</h4>
<p class="statutory-body">The Committee shall be composed of physicians whose clinical practice includes a significant number of patients with acquired immune deficiency syndrome.</p>
<h4 class="subsection-head">(c) Duties</h4>
<p class="statutory-body">The Committee shall&mdash;</p>
<p class="statutory-body-1em">(1) advise the Director of such Institute (and may provide advice to the Directors of other agencies of the National Institutes of Health, as appropriate) on appropriate research activities to be undertaken with respect to clinical treatment of such syndrome, including advice with respect to&mdash;</p>
<p class="statutory-body-2em">(A) research on drugs for preventing or minimizing the development of symptoms or conditions arising from infection with the etiologic agent for such syndrome, including recommendations on the projects of research with respect to diagnosing immune deficiency and with respect to predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases; and</p>
<p class="statutory-body-2em">(B) research on the effectiveness of treating such symptoms or conditions with drugs that&mdash;</p>
<p class="statutory-body-3em">(i) are not approved by the Commissioner of Food and Drugs for the purpose of treating such symptoms or conditions; and</p>
<p class="statutory-body-3em">(ii) are being utilized for such purpose by individuals infected with such etiologic agent;</p>
<br class="Q04" />
<p class="statutory-body-1em">(2)(A) review ongoing publicly and privately supported research on clinical treatment for acquired immune deficiency syndrome, including research on drugs described in paragraph (1); and</p>
<p class="statutory-body-1em">(B) periodically issue, and make available to health care professionals, reports describing and evaluating such research;</p>
<p class="statutory-body-1em">(3) conduct studies and convene meetings for the purpose of determining the recommendations among physicians in clinical practice on clinical treatment of acquired immune deficiency syndrome, including treatment with the drugs described in paragraph (1); and</p>
<p class="statutory-body-1em">(4) conduct a study for the purpose of developing, with respect to individuals infected with the etiologic agent for acquired immune deficiency syndrome, a consensus among health care professionals on clinical treatments for preventing or minimizing the development of symptoms or conditions arising from infection with such etiologic agent.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(July 1, 1944, ch. 373, title XXIII, &sect;2304, as added Pub. L. 100&ndash;607, title II, &sect;201(4), Nov. 4, 1988, 102 Stat. 3065; amended Pub. L. 100&ndash;690, title II, &sect;2617(a), Nov. 18, 1988, 102 Stat. 4240; Pub. L. 103&ndash;43, title XVIII, &sect;1811(1), title XX, &sect;2008(d)(1), June 10, 1993, 107 Stat. 199, 212.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:priorprovisions-note -->
<h4 class="note-head">Prior Provisions</h4>
<p class="note-body">A prior section 300cc&ndash;3, acts July 1, 1944, ch. 373, title XXIII, &sect;2304, formerly title V, &sect;504, 58 Stat. 710; June 25, 1948, ch. 654, &sect;6, 62 Stat. 1018; 1953 Reorg. Plan No. 1, &sect;&sect;5, 8, eff. Apr. 11, 1953, 18 F.R. 2053, 67 Stat. 631; renumbered title XXI, &sect;2104, Apr. 26, 1983, Pub. L. 98&ndash;24, &sect;2(a)(1), 97 Stat. 176; renumbered title XXIII, &sect;2304, Nov. 14, 1986, Pub. L. 99&ndash;660, title III, &sect;311(a), 100 Stat. 3755, related to care of Service patients at Saint Elizabeths Hospital, prior to repeal by Pub. L. 98&ndash;621, &sect;10(s), Nov. 8, 1984, 98 Stat. 3381, effective Oct. 1, 1987. Subsequent to repeal, section 2104 of title XXI of act July 1, 1944, was renumbered section 2304 of title XXIII of that act by section 311(a) of Pub. L. 99&ndash;660.</p>
<p class="note-body">A prior section 300cc&ndash;4, acts July 1, 1944, ch. 373, title XXI, &sect;2105, formerly title V, &sect;505, 58 Stat. 710; 1953 Reorg. Plan No. 1, &sect;&sect;5, 8, eff. Apr. 11, 1953, 18 F.R. 2053, 67 Stat. 631; renumbered title XXI, &sect;2105, Apr. 26, 1983, Pub. L. 98&ndash;24, &sect;2(a)(1), 97 Stat. 176, provided procedures under which the Secretary could settle claims for damages from collisions or incident to the operation of vessels within a year of the accrual of such claims and not to exceed $3,000, prior to repeal by Pub. L. 99&ndash;117, &sect;12(f), Oct. 7, 1985, 99 Stat. 495. Subsequent to repeal, section 2105 of title XXI of act July 1, 1944, was renumbered section 2305 of title XXIII of that act by Pub. L. 99&ndash;660, title III, &sect;311(a), Nov. 14, 1986, 100 Stat. 3755.</p>
<p class="note-body">Prior sections 300cc&ndash;5 to 300cc&ndash;10, act July 1, 1944, &sect;&sect;2306 to 2311, respectively, were successively renumbered by subsequent acts and transferred, see sections 238c to 238h of this title.</p>
<!-- field-end:priorprovisions-note -->
<!-- field-start:amendment-note -->
<h4 class="note-head">Amendments</h4>
<p class="note-body">1993&mdash;Pub. L. 103&ndash;43, &sect;2008(d)(1)(A), substituted &ldquo;Research Advisory Committee&rdquo; for &ldquo;Clinical Research Review Committee&rdquo; in section catchline.</p>
<p class="note-body">Subsec. (a). Pub. L. 103&ndash;43, &sect;2008(d)(1)(B), substituted &ldquo;AIDS Research Advisory Committee&rdquo; for &ldquo;AIDS Clinical Research Review Committee&rdquo;.</p>
<p class="note-body">Subsec. (c)(1). Pub. L. 103&ndash;43, &sect;1811(1), in introductory provisions inserted &ldquo;(and may provide advice to the Directors of other agencies of the National Institutes of Health, as appropriate)&rdquo; after &ldquo;Director of such Institute&rdquo; and in subpar. (A) inserted before semicolon at end &ldquo;,&nbsp;including recommendations on the projects of research with respect to diagnosing immune deficiency and with respect to predicting, diagnosing, preventing, and treating opportunistic cancers and infectious diseases&rdquo;.</p>
<p class="note-body">1988&mdash;Subsec. (c)(2)(B). Pub. L. 100&ndash;690 substituted semicolon for period.</p>
<!-- field-end:amendment-note -->
<!-- field-start:effectivedate-amendment-note -->
<h4 class="note-head">Effective Date of 1988 Amendment</h4>
<p class="note-body">Amendment by Pub. L. 100&ndash;690 effective immediately after enactment of Pub. L. 100&ndash;607, which was approved <!-- PDFPage:993 -->Nov. 4, 1988, see section 2600 of Pub. L. 100&ndash;690, set out as a note under section 242m of this title.</p>
<!-- field-end:effectivedate-amendment-note -->
<!-- field-start:terminationdate-note -->
<h4 class="note-head">Termination of Advisory Committees</h4>
<p class="note-body">Advisory committees established after Jan. 5, 1973, to terminate not later than the expiration of the 2-year period beginning on the date of their establishment, unless, in the case of a committee established by the President or an officer of the Federal Government, such committee is renewed by appropriate action prior to the expiration of such 2-year period, or in the case of a committee established by the Congress, its duration is otherwise provided by law. See section 14 of Pub. L. 92&ndash;463, Oct. 6, 1972, 86 Stat. 776, set out in the Appendix to Title 5, Government Organization and Employees.</p>
<p class="note-body">Pub. L. 93&ndash;641, &sect;6, Jan. 4, 1975, 88 Stat. 2275, set out as a note under section 217a of this title, provided that an advisory committee established pursuant to the Public Health Service Act shall terminate at such time as may be specifically prescribed by an Act of Congress enacted after Jan. 4, 1975.</p>
<!-- field-end:terminationdate-note -->
<!-- field-end:notes -->
<!-- field-start:secref -->
<h4 class="note-head">Section Referred to in Other Sections</h4>
<!-- field-end:secref -->
<!-- field-start:sectionreferredto -->
<p class="note-body">This section is referred to in sections 300cc&ndash;12, 300cc&ndash;14, 300cc&ndash;17, 300cc&ndash;18 of this title.</p>
<!-- field-end:sectionreferredto -->


</body></html>